Top 5 Reasons to Attend

Top 5 Reasons to Attend

  • Find out if there are significant changes coming for the Patented Medicine Prices Review Board (PMPRB) as a result of their strategic review

  • Hear how the market in Quebec is likely to evolve

  • Determine whether or not there should be a national pharmacare program in Canada’s future

  • Gain insights into CADTH’s evolving process in bringing forward costeffective treatments and its approach to orphan drugs

  • Discover the latest thinking on how the path to market can be improved for both new therapies and for biosimilars on the horizon